Parkinson’s disease, a relentless neurodegenerative disorder, impacts an estimated 1 million individuals in the United States and a staggering 10 million globally, presenting a spectrum of debilitating symptoms that profoundly diminish quality of life. These symptoms manifest as involuntary tremors, profound motor control impairments, disruptive sleep disturbances, and a gradual erosion of cognitive faculties. While existing therapeutic interventions, encompassing prolonged pharmaceutical regimens and invasive surgical procedures like deep brain stimulation (DBS), offer symptomatic relief, they fall short of halting the disease’s inexorable advance or providing a definitive cure.
An international consortium of researchers, spearheaded by the Changping Laboratory in China and involving collaborators from Washington University School of Medicine in St. Louis, has unveiled a critical brain circuitry implicated in the core pathological features of Parkinson’s disease. This groundbreaking discovery centers on a neural system designated as the somato-cognitive action network, or SCAN, which the study posits plays a pivotal role in the pathogenesis of this complex condition. Employing a non-invasive neuromodulation technique, transcranial magnetic stimulation (TMS), the research team demonstrated that precisely targeting the SCAN resulted in over a twofold improvement in patient symptoms compared to stimulation of adjacent brain regions.
Published on February 4th in the esteemed scientific journal Nature, these findings represent a significant paradigm shift, challenging established understandings of Parkinson’s disease and heralding a new era of highly localized and personalized therapeutic strategies. Co-author Dr. Nico U. Dosenbach, a distinguished neurologist and professor at WashU Medicine, emphasized the implications of the research, stating, "This work unequivocally establishes Parkinson’s as a disorder of the SCAN, and our data provide compelling evidence that by precisely and individually targeting the SCAN, we can achieve superior therapeutic outcomes than previously conceived." He further posited that modulating activity within the SCAN could potentially decelerate or even reverse the disease’s trajectory, moving beyond mere symptom management.
The SCAN, first meticulously described by Dr. Dosenbach in a 2023 Nature publication, is situated within the motor cortex, the brain’s command center for voluntary movement. Its fundamental function involves the intricate translation of intended actions into physical execution and the subsequent monitoring of these movements. Given that Parkinson’s disease extends its influence beyond motor functions to encompass a wide array of physiological processes, including digestion, sleep regulation, motivation, and cognitive processing, senior author Dr. Hesheng Liu collaborated with Dr. Dosenbach to explore whether dysregulation within the SCAN could account for this pervasive symptomology and simultaneously offer a viable therapeutic target.
To rigorously test this hypothesis, Dr. Liu’s team undertook an extensive analysis of neuroimaging data sourced from over 800 participants enrolled in multi-center research initiatives across both the United States and China. This diverse cohort included individuals diagnosed with Parkinson’s disease undergoing various treatment modalities, such as DBS, TMS, focused ultrasound, and pharmacological interventions, alongside healthy volunteers and individuals with other movement disorders, who served as crucial control groups.
The analytical findings revealed a hallmark characteristic of Parkinson’s disease: an aberrant and excessive degree of connectivity between the SCAN and the subcortex, a deep brain structure integral to emotional processing, memory formation, and motor control. Intriguingly, across all four therapeutic approaches investigated in the study, the most pronounced treatment efficacy was observed when these interventions served to mitigate this heightened inter-regional connectivity. The restoration of a more balanced communication pathway between these brain areas appeared to normalize the intricate neural circuits responsible for action planning and coordination.
"For many decades, the prevailing scientific consensus has linked Parkinson’s disease predominantly to motor deficits and the dysfunction of the basal ganglia, the brain’s primary regulator of muscle activity," commented Dr. Liu. "Our research fundamentally shifts this perspective, demonstrating that the disease originates from a far more widespread network of neural dysfunction. The SCAN exhibits hyperconnectivity with key regions implicated in Parkinson’s, and this disrupted neural architecture not only impairs motor function but also adversely affects related cognitive and autonomic bodily processes."
Building upon these profound insights, the research team devised a sophisticated precision treatment system engineered to target the SCAN with remarkable accuracy, down to the millimeter level, and without the need for surgical intervention. This innovative approach leverages transcranial magnetic stimulation (TMS), a non-invasive technique that delivers precisely calibrated magnetic pulses to specific brain areas via a device positioned on the scalp. In a subsequent clinical trial involving 18 patients who received SCAN-targeted TMS, an impressive 56% demonstrated a significant clinical response after just two weeks of treatment. In stark contrast, only 22% of 18 patients receiving stimulation in adjacent brain regions experienced improvements, underscoring the SCAN-targeted approach’s 2.5-fold greater effectiveness.
Dr. Dosenbach highlighted a significant advantage of non-invasive treatments, noting, "With non-invasive therapies, we have the potential to initiate neuromodulation interventions much earlier in the disease progression than is currently feasible with DBS, as these methods bypass the necessity for brain surgery."
He further cautioned that substantial foundational research remains imperative to fully elucidate the specific contributions of different SCAN sub-regions to the diverse array of Parkinson’s symptoms.
Looking toward the future, Dr. Dosenbach is poised to initiate further clinical trials in collaboration with Turing Medical, a startup company he co-founded affiliated with WashU Medicine. These trials will evaluate a non-invasive therapeutic strategy employing surface electrode arrays positioned over SCAN regions to address gait disturbances, a common and disabling symptom in individuals with Parkinson’s disease. Additionally, he intends to explore low-intensity focused ultrasound as another promising non-invasive modality for modulating SCAN activity through acoustic energy.
This pioneering research received crucial support from numerous entities, including the Changping Laboratory, the U.S. National Institutes of Health (under grants MH096773, MH122066, MH121276, MH124567, NS129521, NS088590, R01NS131405, U01NS098969, and U01NS117836), the National Natural Science Foundation of China (under grants 81527901, 81720108021, 81971689, 31970979, and 82090034), the National Key R&D Program of China (grant 2017YFE0103600), the Intellectual and Developmental Disabilities Research Center, the Kiwanis Foundation, the Washington University Hope Center for Neurological Disorders, and the Collaborative Innovation Center of Neuropsychiatric Disorders and Mental Health of Anhui Province (grant 2020xkjT05). The content presented is exclusively the responsibility of the study authors and does not necessarily reflect the official perspectives of the National Institutes of Health.
Several authors hold financial interests related to this research. Dr. H.L. serves as the chief scientist of Neural Galaxy Inc. Dr. L.L. is a member of the scientific advisory board for Beijing Pins Medical Co., Ltd. and is listed as an inventor on patents and patent applications pertaining to the deep brain stimulator utilized in this study. Dr. N.U.F.D. has a financial stake in Turing Medical Inc. and may benefit financially from the company’s successful commercialization of FIRMM motion monitoring software, BullsAI neuromodulation targeting software, or PACE neuromodulation systems. Dr. E.M.G. and Dr. N.U.F.D. may receive royalty income derived from FIRMM technology developed at Washington University School of Medicine and licensed to Turing Medical Inc. Dr. N.U.F.D. is a co-founder of Turing Medical Inc. These potential conflicts of interest have undergone thorough review and are actively managed by Washington University School of Medicine. Dr. S.L. provides consulting services for Iota Biosciences. Dr. P.A.S. receives fellowship education support from Medtronic and Boston Scientific.
About the Author
